For them, the implant represents a genuine second chance.
For the roughly one-third of epilepsy patients whose seizures resist every available medication, the question has never been one of willpower or patience — it has been one of access to tools capable of reaching where pills cannot. This summer, Intermountain Health's neurosurgery team completed their hundredth brain implant procedure, a milestone that marks not merely a number but a turning point: a once-rare intervention, long confined to elite academic centers, is becoming something closer to a standard of care. In the Mountain West and beyond, a door that was barely ajar is now standing open.
- One in three epilepsy patients cannot be helped by medication alone, leaving them trapped in lives shaped entirely by the unpredictability of seizures.
- Brain implant surgery — placing electrodes that monitor and interrupt seizure activity at its source — offers a direct intervention that no pill can replicate, but until recently it remained out of reach for most patients.
- Intermountain Health's hundredth procedure signals that this technology has crossed a critical threshold: trained surgeons, refined technique, and institutional knowledge are accumulating at a regional health system, not just at distant research hospitals.
- Each successful surgery compresses the distance between experimental and routine, pressuring other health systems, insurers, and training programs to follow suit.
- For patients who regain the ability to drive, work, or simply move through a day without fear, the implant is not a clinical data point — it is the return of a life.
Intermountain Health's neurosurgery team completed their hundredth brain implant procedure this summer, reaching a threshold that signals something larger than a round number. The surgery targets epilepsy patients whose seizures have resisted every available medication — a population representing roughly one-third of all epilepsy cases — by placing electrodes deep in the brain to monitor electrical activity and deliver precise stimulation before a seizure can fully develop.
The procedure is not a cure, but its effects can be transformative. The gap between five seizures a day and one every few weeks is not merely clinical; it is the difference between holding a job, driving a car, and living without the constant shadow of sudden injury. For patients whose standard treatment has already failed them, the implant represents a genuine second chance at an ordinary life.
A decade ago, such surgeries were rare, reserved for the most desperate cases at major academic medical centers. That a regional health system has now performed one hundred of them reflects a meaningful shift — more surgeons trained, technique refined with each procedure, and institutional knowledge compounding in ways that make every subsequent surgery safer and more precise.
The milestone will likely accelerate adoption elsewhere. Other health systems will study the outcomes, train their teams, and begin offering the procedure more widely. Insurers watching improving results will expand coverage. The devices themselves will continue to evolve — smaller, longer-lasting, smarter. What Intermountain Health's hundredth surgery ultimately demonstrates is that the long walk from experimental intervention to standard treatment has been made, and the path behind it is now easier to follow.
Intermountain Health reached a clinical milestone this summer when its neurosurgery team completed their hundredth brain implant procedure designed to control epilepsy seizures. The surgery represents a threshold moment for a technology that, until recently, remained confined to specialized centers and research protocols. For patients whose seizures have resisted every medication available—the roughly one-third of epilepsy cases that doctors call treatment-resistant—the implant offers something medications cannot: direct intervention at the source.
The procedure works by placing electrodes deep within the brain, typically in regions where seizure activity originates. Once positioned, the device monitors electrical patterns and delivers targeted stimulation to interrupt seizures before they fully develop. It is not a cure. But for many patients, it transforms what living with epilepsy means. The difference between having five seizures a day and one every few weeks, or none at all, is not merely clinical—it is the difference between holding a job, driving a car, living without constant fear of injury or death.
That Intermountain Health has now performed one hundred of these surgeries signals something important about the technology's trajectory. A decade ago, such procedures were rare, reserved for the most desperate cases at major academic medical centers. The fact that a regional health system in the Mountain West has now reached this volume suggests the procedure is becoming more routine, more surgeons are trained to perform it, and more patients are gaining access. Each surgery refined the team's technique, expanded their understanding of which patients benefit most, and built institutional knowledge that makes the next procedure safer and more precise than the last.
Epilepsy affects roughly one percent of the global population, but the burden falls disproportionately on those whose seizures do not respond to medication. These patients face not only the seizures themselves—the sudden loss of consciousness, the physical danger, the unpredictability—but also the psychological weight of knowing that standard treatment has failed them. Many become isolated, unable to work or attend school, their lives contracted by the need to avoid triggers and manage risk. For them, the implant represents a genuine second chance.
The milestone also reflects a broader shift in how medicine approaches neurological disease. Rather than waiting for a pharmaceutical breakthrough that may never come, clinicians are increasingly willing to intervene surgically in carefully selected cases. The implant is not for everyone—it requires brain surgery, carries inherent risks, and works better for some seizure types than others. But for the right patient, the calculus is straightforward: the risk of surgery is worth taking if it means reclaiming a life that seizures have stolen.
Intermountain Health's achievement of one hundred procedures will likely accelerate adoption elsewhere. Other health systems will see the data, train their surgeons, and begin offering the procedure to their own patients. Insurance companies, watching outcomes improve and costs stabilize, will expand coverage. The technology itself will continue to evolve—devices will become smaller, battery life will extend, algorithms will grow smarter at detecting and preventing seizures. What matters now is that the path from experimental procedure to standard treatment has been walked, and the door is open wider than it was before.
La Conversación del Hearth Otra perspectiva de la historia
Why does reaching one hundred procedures matter? Isn't it just a number?
It's the moment when something stops being experimental and becomes normal. When you've done a hundred of something, you've trained multiple surgeons, refined your technique, built a track record. Other hospitals start paying attention. Insurance companies start covering it. Patients stop thinking of it as a last resort and start thinking of it as an option.
What happens to someone's life if the implant works?
Everything changes. A patient who was having five seizures a day, who couldn't drive or work or be alone, suddenly has weeks without a seizure. They get their independence back. They can plan a future instead of just managing the next crisis.
And if it doesn't work?
Then you've had brain surgery for nothing, which is why the selection process is so careful. But for the patients it does work for—the ones whose medications have all failed—the risk is worth it. The alternative is a life constrained by seizures.
How many epilepsy patients actually need this?
About a third of people with epilepsy don't respond to medication. That's millions of people worldwide living with uncontrolled seizures. Most of them don't have access to this surgery yet. That's why the milestone matters—it's proof the procedure can be done safely at scale, which means more hospitals will offer it.
What's next for the technology?
The devices will get better. Smaller, longer-lasting batteries, smarter algorithms that predict seizures before they happen. But the real next step is access. Right now this is available at major medical centers. The question is how quickly it spreads to community hospitals and smaller health systems.